AwardTape · Defense awards · Research and development · Health R&D · HT942525C0035
HT942525C0035: $9.6M definitive contract to Hemoglobin Oxygen Therapeutics LLC
Hemoglobin Oxygen Therapeutics LLC holds a definitive contract from Defense Health Agency with $9.6M obligated since Oct 2023, against a ceiling of $12.5M. Latest action Mar 16, 2026.
Canine oxygen carrier manufacturing restoration and regulatory activities
| PIID | HT942525C0035 |
|---|---|
| Type | definitive contract |
| Company | Hemoglobin Oxygen Therapeutics LLC |
| Agency | Defense Health Agency |
| Contracting office | DEFENSE HEALTH AGENCY |
| Category | Research and development · Health R&D |
| PSC | AN13 HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| NAICS | 541715 RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| Obligated since Oct 2023 | $9.6M |
| Total obligated (lifetime) | $9.6M |
| Ceiling (base and all options) | $12.5M |
| Base date | May 22, 2025 |
| Latest action | Mar 16, 2026 |
| End date | May 31, 2029 |
| Actions since Oct 2023 | 6 |
| Pricing | Firm fixed price |
| Competition | Not competed |
| Place of performance | PA |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial